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BACKGROUND: Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1
through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor
a (PDGFRa), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling net-
works implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced,
radioiodine-refractory, differentiated thyroid cancer (RR-DTC). METHODS: Fifty-eight patients with RR-DTC who had disease progres-
sion during the previous 12 months received lenvatinib 24 mg once daily in 28-day cycles until disease progression, unmanageable
toxicity, withdrawal, or death. Previous VEGFR-targeted therapy was permitted. The primary endpoint was the objective response
rate (ORR) based on independent imaging review. Secondary endpoints included progression-free survival (PFS) and safety. Serum
levels of 51 circulating cytokines and angiogenic factors also were assessed. RESULTS: After 14 months of follow-up, patients had an
ORR of 50% (95% confidence interval [CI], 37%-63%) with only partial responses reported. The median time to response was 3.6
months, the median response duration was 12.7 months, and the median PFS was 12.6 months (95% CI, 9.9-16.1 months). The ORR for
patients who had received previous VEGF therapy (n5 17) was 59% (95% CI, 33%-82%). Lower baseline levels of angiopoietin-2 were
suggestive of tumor response and longer PFS. Grade 3 and 4 treatment-emergent adverse events, regardless of their relation to
treatment, occurred in 72% of patients and most frequently included weight loss (12%), hypertension (10%), proteinuria (10%), and di-
arrhea (10%). CONCLUSIONS: In patients with and without prior exposure to VEGF therapy, the encouraging response rates, median
time to response, and PFS for lenvatinib have prompted further investigation in a phase 3 trial. Cancer 2015;121:2749-56. VC 2015 The
Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the
terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited and is not used for commercial purposes.
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INTRODUCTION
Differentiated thyroid cancer (DTC) includes papillary and follicular histologies and accounts for 90% of all thyroid
cancers,1 2% of all cancers (180,000 globally), but<0.5% of all cancer deaths, and 90% of patients survive10 years.2-4
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However, patients with radioiodine-refractory DTC (RR-
DTC) have a 10-year survival rate of only 10% from the
detection of distant metastases.5 Consensus guidelines
have recommended clinical trials with systemic therapies
targeted to specific molecules, because traditional cyto-
toxic agents have demonstrated marginal efficacy and sig-
nificant toxicities.6-8
Multiple molecular signaling pathways have been
implicated in the pathogenesis of DTC and are potential
targets for therapy.9 Specifically, alterations in several mo-
lecular signaling pathways, including B-raf proto-onco-
gene, serine/threonine kinase (BRAF), v-ras oncogene
homolog (RAS), fibroblast growth factor receptor
(FGFR), and ret proto-oncogene (RET), have been impli-
cated in the pathogenesis and proliferation of DTC. Fur-
thermore, tumor angiogenesis, primarily mediated by
vascular endothelial growth factor receptor 2 (VEGFR2),
has been associated with metastatic disease, increased re-
currence, and shorter disease-free survival.10 Receptor ty-
rosine kinase inhibitors (TKIs) with activity on these
angiogenic pathways have demonstrated efficacy in clini-
cal trials of patients with RR-DTC.11-13 Recently, 1 such
therapy (sorafenib) was approved by the US Food and
Drug Administration and by the European Medicines
Agency for the treatment of RR-DTC,13 and another TKI
(vandetanib) is currently being investigated in a phase 3
clinical study for the same indication. In addition, com-
ponents of these signaling pathways—as well as others—
have been investigated for their potential to provide infor-
mation with respect to patient prognosis or response to
TKI therapy in thyroid cancer.14,15
Lenvatinib (E7080; Eisai Inc, Woodcliff Lake NJ) is
an oral, multitargeted TKI of VEGFR1, VEGFR2, and
VEGFR3; FGFR1, FGFR2, FGFR3, and FGFR4;
platelet-derived growth factor receptor a (PDGFRa);
RET; and v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog (KIT).16-18 Preliminary evidence of
efficacy in phase 1 trials of lenvatinib in a variety of solid
tumor types, including the thyroid,19,20 prompted the ini-
tiation of this phase 2 trial to investigate its efficacy and
safety in patients with RR-DTC. In addition, this report
presents findings from the correlations of lenvatinib treat-
ment outcomes with levels of circulating cytokines and
angiogenic factors (CAFs).
MATERIALS AND METHODS
This open-label, single-arm, phase 2 trial (clinicaltrials.-
gov identifier: NCT00784303) of oral lenvatinib for the
treatment of RR-DTC was conducted at 30 sites in 6
countries. Treatment consisted of lenvatinib 24 mg
administered once daily for a minimum of eight 28-day
cycles; discontinuations occurred because of disease pro-
gression, unacceptable toxicity, withdrawal, or death.
Two patients received lenvatinib 10 mg twice daily before
a protocol amendment that identified the dose as 24 mg
once daily. Protocol-directed dose reductions occurred for
all grade 2 adverse events (AEs), except for hyperten-
sion, nausea, and vomiting, which were managed first by
optimum medical treatment. Once the dose was reduced,
it could not be increased. All patients provided signed
informed consent before entry, and the study was
approved by the institutional review board at each partici-
pating site and was carried out in accordance with the
Declaration of Helsinki and in accordance with an assur-
ance filed with and approved by the US Department of
Health and Human Services.
PATIENTS
Patients were aged 18 years who had histologically con-
firmed DTC (including papillary, follicular, H€urthle cell,
and poorly differentiated) that proved to be radioiodine-
refractory (see online supporting information), evidence
of measurable and progressive disease (PD) (according to
modified Response Evaluation Criteria In Solid Tumors,
version 1.0)21 within the previous 12 months, and an
Eastern Cooperative Oncology Group performance status
of 0 to 2. The receipt of prior chemotherapy or antiangio-
genic therapy was permitted; however, it must have been
discontinued at least 30 days before study entry. Patients
with anaplastic thyroid cancer; central nervous systemme-
tastasis; active hemoptysis; bleeding or thrombotic
disorders; receipt of anticoagulants; or significant cardio-
vascular, hematopoietic, hepatic, or renal dysfunction
were excluded.
Patient Monitoring and Tumor Assessment
Pretreatment tumor assessments using computed tomog-
raphy scans of the neck, chest, abdomen, pelvis, and other
areas of known or newly suspected disease were performed
within 4 weeks before the first dose and then every 8
weeks, and bone scans were obtained every 4 cycles.
Responses (complete response [CR] or partial response
[PR]) were confirmed at a repeat tumor evaluation at least
4 weeks after they were first observed. For a designation of
stable disease (SD) as the best overall response, at least 1
post-treatment measurement must have met SD criteria a
minimum of 7 weeks after the first dose. Patients who
achieved SD for6months or who had a PR but had pro-
gression in a single bony metastasis were permitted to
receive palliative radiotherapy at the single site followed
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by the resumption of lenvatinib treatment. These patients
had previously met criteria for PD at the time progression
was documented in the single bone metastasis. Patients
who discontinued treatment before they developed PD
continued to undergo tumor assessment every 3 months
from the last assessment until PD was documented or dif-
ferent treatment was initiated. Blood samples for serum
protein biomarkers were collected at baseline (cycle 1, day
1), 8 days post-treatment (cycle 1, day 8), and 36 days
post-treatment (cycle 2, day 8).
Assessment of Clinical Endpoints
The primary endpoint was the objective response rate
(ORR), defined as a CR or a PR based on modified
Response Evaluation Criteria In Solid Tumors, version
1.0, by an independent imaging review (IIR). Secondary
endpoints included progression-free survival (PFS), over-
all survival, time to response, response duration, safety,
and tolerability. PFS was defined as the time during and
after treatment during which the patient was alive and
without PD. Prespecified subgroup analyses of the pri-
mary endpoint were based on the following criteria: age
(<65 years, 65 years), sex, race (white, nonwhite), and
previous receipt of VEGFR-targeted therapy.
Biomarker Assessments
A panel of 51 CAFs was assayed using enzyme-linked im-
munosorbent assays and multiplex assays. Sample data ac-
quisition and analysis were performed on either an
enzyme-linked immunosorbent assay plate reader using
SoftmaxPro software (Molecular Devices, Sunnyvale,
Calif) or the Bio-Rad Bio-Plex System (Bio-Rad Labora-
tories, Hercules, Calif) using Bio-Plex Manager 4.1 soft-
ware for multiplex assays (Bio-Rad Laboratories). CAFs
for which >20% of patients had out-of-range measure-
ments were not used for the correlative analyses.
Statistical Analyses
All patients who had received at least 1 dose of lenvatinib
(the intent-to-treat population) were included in the pri-
mary efficacy analyses. The safety population included all
patients who had received at least 1 dose of study medica-
tion and at least 1 post-treatment safety assessment. In
this study, the intent-to-treat and safety populations were
identical. The ORR was calculated at the end of the treat-
ment phase, when patients had completed 8 cycles or
had discontinued before this, and are presented with 2-
sided 95% Clopper and Pearson confidence intervals
(CIs). Patient demographic data and safety parameters
were summarized using descriptive statistics. Sample size
estimates based on the Simon optimal 2-stage design
assumed a5 .05, 90% power, and an expected ORR of
15% with lenvatinib compared with 2.5% based on his-
toric controls. Unexpectedly rapid enrollment resulted in
completion of the second stage before the scheduled in-
terim cutoff; consequently, the optimal 2-stage design was
not implemented. Median PFS and overall survival are
presented with 2-sided 95%CIs and were calculated using
the Kaplan-Meier method and plotted over time after
therapy. Clinical statistical analyses were performed using
Statistical Analysis System software (UNIX version 8.2
andWindows version 9.1; SAS Institute, Cary, NC).
Post-treatment fold changes in serum biomarker lev-
els from baseline (cycle 1, day 1) were analyzed using the
Wilcoxon signed-rank test for paired samples. Wilcoxon
signed-rank tests also were used to analyze the correlation
of baseline serum biomarker levels and objective
responses. To test for associations between PFS and base-
line serum biomarkers, log-transformed values were used
as independent variables in univariate Cox proportional
hazard models with Wald-test P values. False discovery
rate analyses were performed to adjust for multiple test-
ing; however, unadjusted P values were considered
because of the exploratory nature of the biomarker analy-
ses. Statistical analyses were performed using R version
2.15.0 or later (R Foundation for Statistical Computing,
Vienna, Austria) with the survival and doMC (parallel
computation) packages.
RESULTS
Between October 2008 and February 2010, 58 patients
with DTC were treated (the intent-to-treat population)
(Table 1). The median patient age was 63 years, the
median weight was 81.1 kg, and most patients were
men (59%), white (86%), and had a baseline Eastern
Cooperative Oncology Group performance status 1
(93%). Prior VEGFR-targeted therapy was reported in
29% of patients. The most common sites of distant me-
tastases were lung (93%), hilar-mediastinal lymph nodes
(57%), and bone (45%). Thirty-five patients (60%) dis-
continued treatment primarily for PD (31%) and AEs
(24%), in addition to patient choice (3%) and with-
drawal of consent (2%); whereas 23 patients (40%) con-
tinued on treatment.
Efficacy
After a minimum follow-up of 14 months, the ORR was
50% (Clopper-Pearson 95% CI, 37%-63%) as assessed
by IIR, and only PRs were reported (Table 2). No differ-
ences in the ORR according to age or sex were observed
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(Table 2, Supporting Fig. 1; see online supporting infor-
mation). In addition, the ORR according to prior
VEGFR-targeted therapy was similar (the ORR was
59% [10 of 17 patients] for those who had received prior
VEGFR-targeted therapy and 46% [19 of 41 patients]
for those who had not received such therapy). Ten of 14
patients who had previously received sorafenib had PRs,
for an ORR of 71%. In an analysis of tumor response
according to histology, 24 of 43 patients (56%) with
papillary thyroid carcinoma and 5 of 15 patients (33%)
with follicular thyroid cancer had PRs. A difference in
ORR was observed between nonwhites and whites (Sup-
porting Fig. 1; see online supporting information); how-
ever, this may have been because of the skewed racial
demographic of the study population (Table 1). Overall,
29 patients (50%) patients achieved a PR, 25 patients
(43%) attained SD (7 weeks), and 16 patients (28%)
experienced durable SD (23 weeks). A waterfall plot of
each efficacy-evaluable patient’s maximum percentage
tumor change in the sum of the greatest dimensions
from baseline to postbaseline nadir is provided in
Figure 1a.
The median time to response was 3.6 months
(95% CI, 1.8-3.7 months) based on IIR, and the me-
dian response duration was 12.7 months (95% CI, 8.8
months to not evaluable [NE]). The median PFS was
12.6 months (95% CI, 9.9-16.1 months) (Fig. 1b) and
was similar in patients who received (PFS, 12.2 months;
95% CI, 7.9 months to NE) or did not receive (PFS,
12.6 months; 95% CI, 9.1 months to NE) prior
VEGFR-targeted therapy. The 6-month PFS rate was
78% (95% CI, 64%-87%), and the 12-month PFS rate
was 55% (95% CI, 40%-67%). In an analysis of PFS in
which patients were censored at the time of drug with-
drawal (ie, at the last tumor assessment within 30 days
of the last study treatment), the median PFS was 15.9
months (95% CI, 10.8 months to NE) (Supporting Fig.
2; see online supporting information). At the time of
analysis, the median overall survival could not be reli-
ably estimated based on the Kaplan-Meier analysis pre-
sented in Supporting Figure 3 (see online supporting
information). Exploratory biomarker analyses are
TABLE 2. The Best Overall Tumor Response Determined by Independent Imaging Review
No. of Patients (%)
Tumor Response Overall, n558
Prior VEGFR-Targeted
Therapy, n5 17
No Prior VEGFR-Targeted
Therapy, n5 41
PR 29 (50) 10 (59) 19 (46)
SD 7 wk 25 (43) 6 (35) 19 (46)
Durable SD 23 wk 16 (28) 5 (29) 11 (27)
Progressive disease 3 (5) 1 (6) 2 (5)
Unevaluable 1 (2) 0 (0) 1 (2)
ORR: CR1PR [95% CI] 29 (50) [37%-63%] 10 (59) [33%-82%] 19 (46) [31%-63%]
Abbreviations: CI, confidence interval; CR, complete response; ORR, objective response rate; PR, partial response; SD, stable disease; VEGFR, vascular endo-
thelial growth factor receptor.
TABLE 1. Patient Demographics and Baseline
Characteristics
Characteristic No. of Patients (%)
Total no. 58 (100)
Age: Median [range], y 63 [34-77]
Sex
Women 24 (41)
Men 34 (59)
Race
Nonwhite 8 (14)
White 50 (86)
Weight, kg
Mean 6SD 84.66 22
Median [range] 81.1 [47-158]
ECOG performance status
0 30 (52)
1 24 (41)
2 4 (7)
NYHA classification
I 51 (88)
II 6 (10)
III 0 (0)
IV 0 (0)
Missing 1 (2)
Histology subtype
Papillary 43 (74)
Follicular, including H€urthle cell 15 (26)
Size of baseline target lesions: Mean6SD, mm 116.7677.6
Prior treatment
Prior VEGFR-targeted therapya 17 (29)
Axitinib 1 (2)
Motesanib 1 (2)
Sorafenib 14 (24)
Sunitinib 3 (5)
Prior anthracycline therapy 8 (14)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NYHA, New
York Heart Association; SD, standard deviation; VEGFR, vascular endothe-
lial growth factor receptor.
a One patient received motesanib and sunitinib, and 1 patient received both
sorafenib and sunitinib.
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presented in Supporting Figures 4 and 5 (see online sup-
porting information).
Treatment Duration and AEs
The median treatment duration was 13.5 cycles (range, 1-
19 cycles). Treatment-emergent AEs (TEAEs) led to dose
interruptions, reductions, or study drug withdrawal in
74%, 66%, and 26% of patients, respectively. All patients
experienced TEAEs, which most frequently were hyperten-
sion (76%), weight decrease (69%), diarrhea (67%), pro-
teinuria (64%), fatigue (60%), decreased appetite (52%),
and nausea (50%) (Table 3). Most hypertension and pro-
teinuria events were grade 1 or 2 and were managed with-
out dose adjustments or withdrawal of treatment.
Common toxicity criteria grade 3 or 4 TEAEs
occurred in 42 patients (72%). Six grade 4 TEAEs were
reported and included hypocalcemia, hyperkalemia, abasia,
and acute myocardial infarction (1 report each) and 2
reports of pulmonary embolism. However, no grade 4
events occurred in 5% of patients. Grade 3 TEAEs that
occurred in at least 5% of patients included weight loss
(12%); hypertension, proteinuria, and diarrhea (10% each);
fatigue (9%); dehydration (9%); and arthralgia (5%).
TEAEs that led to lenvatinib withdrawal and occurred in at
least 2 patients were proteinuria (5%), pulmonary embo-
lism (3%), and deep vein thrombosis (3%). Skin-related
TEAEs included palmar-plantar erythrodysesthesia (PPE)
syndrome (22%; including grade 3 PPE in 1 patient [2%]),
rash (14%), dry skin (14%), and alopecia (9%).
Nonfatal, serious AEs occurred in 28 patients
(48%), and those that occurred in at least 2 patients
included dehydration (7%), hypotension (5%), pulmo-
nary embolism, lower abdominal pain, hypertension, and
cardiac failure (3% each). Three deaths occurred within
30 days of the last dose of lenvatinib: 1 patient died from
TABLE 3. The Most Common (25%) Treatment-
Emergent Adverse Events
No. of Events (%)a
TEAEb
All-Grade TEAEs,
n558 Grade 3 TEAEsc
Hypertension 44 (76) 6 (10)
Weight decreased 40 (69) 7 (12)
Diarrhea 39 (67) 6 (10)
Proteinuria 37 (64) 6 (10)
Fatigue 35 (60) 5 (9)
Decreased appetite 30 (52) 1 (2)
Nausea 29 (50) 0 (0)
Cough 26 (45) 1 (2)
Dysphonia 25 (43) 0 (0)
Headache 25 (43) 1 (2)
Vomiting 22 (38) 0 (0)
Arthralgia 21 (36) 3 (5)
Dry mouth 20 (35) 0 (0)
Back pain 19 (33) 2 (3)
Pain in extremity 19 (33) 0 (0)
Dyspnea 18 (31) 0 (0)
Musculoskeletal pain 18 (31) 1 (2)
Stomatitis 18 (31) 1 (2)
Abdominal pain upper 18 (31) 1 (2)
Abdominal pain 16 (28) 1 (2)
Epistaxis 16 (28) 0 (0)
Abbreviation: TEAEs, treatment-emergent adverse events.
a Patients with TEAEs were counted only once even if they had >1 event.
b Two patients died from serious adverse events (arterial hemorrhage and
cardiac arrest).
c No grade 4 TEAEs were reported for the listed events.
Figure 1. Lenvatinib efficacy results are illustrated. (a) This
waterfall graph illustrates the percentage change in the
summed greatest dimension of target lesions from baseline
to nadir (evaluable population, n555). PD indicates progres-
sive disease; PR, partial response; SD, stable disease; VEGFR,
vascular endothelial growth factor receptor. (b) This Kaplan-
Meier estimate of progression-free survival was based on
data from an independent imaging review (intent-to-treat
population, n558). CI indicates confidence interval.
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PD, and 2 patients died after serious AEs (1 arterial hem-
orrhage and 1 cardiac arrest).
DISCUSSION
Historically, there have been limited treatment options
for patients with RR-DTC. Multitargeted TKI agents
under investigation for the treatment of RR-DTC have
demonstrated response rates ranging between 8% and
49% and PFS ranging between 10.8 months and 18.1
months.13,22-26 In the current study, lenvatinib treatment
was associated with an ORR of 50% (all PRs), as deter-
mined by IIR, and a durable (23 weeks) SD rate of
28%. The median PFS was 12.6 months. Similar tumor
responses were observed for patients who did or did not
receive prior VEGFR-targeted therapy. This finding may
have important clinical implications, because the use of
VEGFR-targeted therapy in RR-DTC is likely to increase
in the near future given the approval of sorafenib and len-
vatinib as well as the investigation of vandetanib in a phase
3 trial for this indication.
All patients who received treatment on this
study had PD within the 12 months before enroll-
ment. The mean sum size of target lesions in these
patients was 11.7 cm, and nearly half of the patients
(45%) had bone metastasis. It is noteworthy that the
majority of patients in this study were men (59%),
consistent with other clinical trials of DTC.22,25
Although DTC is more prevalent in women, men
typically have a worse prognosis,27 which may explain
their over-representation in clinical studies.
Although comparisons cannot be drawn from dif-
ferent clinical trials, the median PFS for lenvatinib of
12.6 months in our study was similar to that reported
in the literature for patients who received other multi-
targeted TKIs.13,22-26 Although those trials supported
the use of multitargeted TKIs, they had different entry
criteria, and some also included medullary and anaplas-
tic thyroid cancers, which behave quite differently.28
Not all studies required evidence of disease progression
for eligibility, which was required in the current study.
It is difficult to determine whether the inclusion of
patients with SD in the other studies may have influ-
enced observed efficacy.
Lenvatinib had a toxicity profile principally charac-
terized by hypertension, proteinuria, fatigue, and gastro-
intestinal complaints, which generally were manageable
with standard medical care and dose interruption or
reduction when necessary. TEAEs resulted in dose inter-
ruptions, reductions, or treatment withdrawals in 74%,
66%, and 26% of patients, respectively. Grade 3 or 4
TEAEs were experienced by 72% of patients, and 48% of
patients had nonfatal, serious AEs. The most common
grade 3 TEAEs were weight decrease (12%); hyperten-
sion, proteinuria, and diarrhea (10% each); and fatigue
and dehydration (9% each). Hypertension and proteinu-
ria have been commonly reported for other VEGFR-
targeted therapies.22,29 Most patients with hypertension
and proteinuria were managed successfully without lenva-
tinib dose adjustments. It is noteworthy that, in the cur-
rent trial, skin-related TEAEs—specifically grade 1 or 2
rash—occurred in 8 patients (14%), and grade 3 PPE syn-
drome occurred in 1 patient (2%). There were 3
treatment-emergent deaths, including 1 patient who died
after experiencing an arterial hemorrhage and 1 patient
who died after a cardiac arrest. Thromboembolic events
are known AEs associated with VEGFR inhibitors.30
These findings underscore the importance of careful
screening to ensure that only patients who have clinically
significant disease are included for treatment.
In this hypothesis-generating, exploratory bio-
marker analysis, changes were observed in the levels of 16
of the 51 CAFs assessed after 8 days of lenvatinib treat-
ment. These included increases in the VEGFR ligands
VEGFA and placental growth factor and decreases in
angiopoietin-2, soluble TEK tyrosine kinase 2 (TIE2),
and soluble VEGFR2. Angiopoietins, including
angiopoietin-2, are ligands of TIE2; and together with
VEGFA, they form a critical interface of the angiogenic
network to promote the initiation and maturation of new
blood vessels.31,32 The angiopoietin-2/angiopoietin-1/
TIE2 axis may either promote or inhibit the formation of
tumors in different contexts.32 The exact role of
angiopoietin-2 in this signaling pathway is complex, act-
ing as either an antagonist or a partial agonist for TIE2.
Nevertheless, anticancer approaches that inhibit
angiopoietin-2 to augment VEGF-targeted therapies
appeared promising in preclinical and early clinical stud-
ies.33 In addition, angiogenic factors like angiopoietin-2
are potential markers for resistance to therapy, and up-
regulation of angiopoietin-2 has been implicated in the
development of resistance to antiangiogenic TKIs in other
cancers.34,35 These findings warrant further investigation
in a larger population.
In summary, our trial of once-daily oral lenvati-
nib in patients with RR-DTC demonstrated an ORR
of 50%, a time to response of 3.6 months, and a
median PFS of 12.6 months, supporting further eval-
uation of lenvatinib in this patient population. Results
from an international, multicenter, randomized phase
3 trial recently were published.36
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